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Abstract In 2003, the Swiss guidelines to prevent vitamin
K deficiency bleeding (VKDB) were adapted. As two oral
doses (2 mg, hour/day 4) of mixed micellar VK preparation
had failed to abolish late VKDB, a third dose (week 4) was
introduced. This report summarizes the new guidelines ac-
ceptance by Swiss pediatricians and the results of a prospec-
tive 6-year surveillance to study their influence on the
incidence of VKDB. The new guidelines acceptance by
Swiss pediatricians was evaluated by a questionnaire sent
to all pediatricians of the Swiss Society of Paediatrics. With
the help of the Swiss Paediatric Surveillance Unit, the inci-
dence of VKDB was monitored prospectively from July 1,
2005 until June 30, 2011. Over a 6-year period (458,184 live
births), there was one case of early and four cases of late
VKDB. Overall incidence was 1.09/105 (95 % confidence
intervals (CI) 0.4–2.6). Late VKDB incidence was 0.87/105
(95 % CI 0.24–2.24). All four infants with late VKDB had an
undiagnosed cholestasis at the time of bleeding; parents of 3/
4 had refused VK prophylaxis, and in 1/4, the third VK dose
had been forgotten. Comparedwith historical control who had
received only two oral doses of mixed micellar VK (18 cases
for 475,372 live births), the incidence of late VKDB was
significantly lower with three oral doses (Chi2,Yates
correction, P00.007). Conclusion VKDB prophylaxis with
3×2 mg oral doses of mixed micellar VK seems to prevent
adequately infants from VKDB. The main risk factors for
VKDB in breast-fed infants are parental VK prophylaxis
refusal or an unknown cholestasis.
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Introduction
In 2003, the Swiss national guidelines to prevent vitamin K
deficiency bleeding (VKDB) were adapted on the basis of a
surveillance report [7, 8]. As it had been shown that two
2-mg oral doses (4 h, 4 days) of mixed micellar vitamin K
preparation had failed to abolish VKDB, mainly late
VKDB, a third 2 mg oral dose (4 weeks) was introduced
in the hope it would permit complete eradication of VKDB.
This report summarizes the new guidelines acceptance by
Swiss pediatricians and the results of a prospective 6-year
surveillance to study their influence on the incidence of VKDB.
Subjects and methods
The new guidelines acceptance by Swiss pediatricians was
evaluated by a questionnaire sent 3 years after their publica-
tions to all 728 pediatricians of the Swiss Society of Paediatrics.
The Swiss Paediatric Surveillance Unit (SPSU) has been
described previously [15] and is comparable to other nation-
al surveillance units [2]. Briefly, using an internationally
accepted definition of VKDB [11], data were collected from
July 1, 2005 until June 30, 2011. Early and classical VKDB
are defined as bleeding occurring on the first day of life,
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respectively, between the second and seventh day. Late
VKDB is defined by the following criteria: (1) occurrence
between the eighth day and the completed 12th week of life;
(2) Quick values ≤15 %, INR ≥4, prothrombin time ≥4 times
the control value; and (3) at least one of the following:
normal or increased platelet count, normal fibrinogen and
absence of fibrin degradation products, or return of pro-
thrombin time to normal values after VK administration.
Cases occurring between the 13th and 26th week of life
were also collected and described as late-onset VKDB.
In the present report, our 6-year experience is summa-
rized and the incidence of VKDB is compared with Swiss
historical controls from the 1995 to 2001 period [7] as well
as reported incidence figures from other countries. The 95 %
confidence intervals (CI) were computed according to
Clopper-Pearson [3]. Chi square test with Yates correction
for continuity [4] was used for comparison of different study
populations. There were 458,184 live births in Switzerland
during the study period (personal communication, C. Di
Loreto, Swiss Federal Statistical Office).
Results
Out of 728 pediatricians, 629 replied (86 %) to the ques-
tionnaire. Six hundred eleven were directly involved with
vitamin K prophylaxis: 586 (96 %) prescribed it according
to the 2003 guidelines, 19 (3 %) depending whether the
infants were breast or bottle fed and 6 (1 %) never, 2 of
whom because they either forgot or had not been informed
of the new guidelines.
The response rate of the surveyed units was 100 %.
Figure 1 shows the breakdown of the 11 reported cases.
Details of five confirmed VKDB are shown in Table 1: there
Number of live borns 
in 6-years study period
n = 458'184
Number of reported 
cases of VKDB
n = 11
Excluded
n = 6
Included
n = 5
Early VKDB
n = 1
Classical VKDB
n = 0
Late VKDB
n = 4
One 13 weeks old infant with intracranial 
bleeding after adequate vitamin K prophylaxis 
but with insufficient vitamin K substitution 
despite low Quick values and known cholestasis
One 11 months old infant with hematuria and 
cystic fibrosis
One 7 weeks old infant without prophylaxis 
(parents refusal) with post traumatic intracranial 
bleeding
One 9 days old infant without prophylaxis 
(parents refusal) with intracranial bleeding 
secondary to septicemia
One case reported twice
Fig. 1 Breakdown of patients
with VKDB
358 Eur J Pediatr (2013) 172:357–360
were one case of early and four cases of late VKDB. All of
the four late VKDB infants were fully breast fed and had
previously unrecognized cholestasis at the time of bleeding,
three had received no prophylactic VK because of parents’
refusal, and one had received only the day 1 and 4 VK doses
as the third had been omitted. By definition [11], only case
no. 1 represents an “idiopathic” case. The other four infants
are secondary cases. These five cases represent prophylactic
failures as, although refused or omitted, the advised prophy-
laxis did not prevent them from bleeding. However, no case
represents a true prophylactic failure (VKDB after adequate
prophylaxis and without predisposing factor). The main risk
factors for VKDB were VK prophylaxis refusal by parents
and/or an unknown cholestatic liver disease. One additional
case of late-onset VKDB presented at week 24 with intesti-
nal bleeding after adequate neonatal prophylaxis, being fully
breastfed but with unknown cholestasis.
Overall, the incidence of late VKDB was 0.87/105 (95 %
CI 0.24–2.24). Compared with the 1995–2001 data [7],
there were significantly less late VKDB (Chi square test
with Yates correction for continuity, P00.007). If patients
who had received no or incomplete VK prophylaxis were
excluded, the incidence of late VKDB was 0.00/105 (95 %
CI 0.00–0.81). If patients with cholestatic liver disease and
inappropriate VK prophylaxis were excluded, the incidence
of late VKDB was 0.00/105 (95 % CI 0.00–0.81).
Discussion
In a nationwide prospective surveillance study including
almost half a million live births, we have shown that VKDB
could be eradicated in healthy infants who benefit from 3×
2 mg oral mixed micellar VK (hour 4, day 4, week 4). The
main risk factors for VKDB were VK prophylaxis refusal by
parents and/or an unknown cholestatic liver disease. Com-
pared with historical controls that benefitted from 2×2 mg
oral mixed micellar VK [7], 3×2 mg oral doses decreased
significantly the risk of late VKDB.
In a previous nationwide questionnaire, we had shown
that 99 % of all obstetric units in Switzerland followed the
official guidelines (2 mg oral mixed micellar VK at hour and
day 4) for VKDB prevention [9]. In the present study, we
have found that 96 % of pediatricians who prescribed pro-
phylactic VK followed the most recent guidelines (third
dose of 2 mg oral mixed micellar vitamin K at week 4).
We are thus fairly confident that our study population was
very homogeneous with regard of the prophylactic regimen
whose efficacy could therefore be appropriately tested on a
large scale basis as in the present study.
There is still an ongoing debate about the most appropri-
ate regimen for late VKDB prophylaxis [1, 6, 7, 9, 10,
12–14]. Different prophylactic schemes are used even with-
in the same country. The lowest incidences of VKDB,
especially late VKDB, are reported after a single intra mus-
cular (im) 1 mg phylloquinone prophylaxis at birth or after
im or oral 2 mg at birth followed by weekly 1 mg oral VK
administration. The incidence of late VKDB after three oral
doses of mixed micellar VK has been estimated to be 0.44/
105 (95 % CI 0.19–0.87) in Germany [14]. The present
study has confirmed that the already known risk factors for
oral prophylactic failure was mainly VK refusal and/or
unknown cholestasis [1, 7]. Refusal of im prophylaxis has
also been reported as a main risk factor for prophylactic
failure [6]. If parental refusal is the commonest reason for
prophylactic failure, it is surprising to us that a policy of
giving a single im injection appears to offer better protection
than the three oral doses. It also surprises us that in none of
the infants reported by van Hasselt et al. [12], prophylaxis
had been refused, suggesting greater parental acceptance of
prophylaxis in Holland and Denmark than in Switzerland
(also oral), New Zealand [1], or the UK [6].
Our findings of an incidence of 0.00/105 (95 % CI 0.00–
0.81) late VKDB in infants with adequate prophylaxis with
3×2 mg oral mixed micellar VK strongly suggests that such
a prophylactic regimen is adequate for healthy infants.
Infants with cholestasis could eventually benefit from an-
other prophylaxis scheme such as the Danish regimen
(mixed micellar VK: 2 mg im at birth or 2 mg oral at birth
Table 1 Confirmed cases of VKDB
Case no. Vitamin K prophylaxis Breast feeding Age at bleeding Localisation of bleeding Hepatobiliary disease Outcome
1 None (parents refusal) Full 18 h Intestinal; Intracranial None Good
2 None (parents refusal) Full 13 days Umbilical Biliary atresia Good
3 None (parents refusal) Full 4 weeks Intestinal; Intracranial Cholestasis (tot/dir serum bili. 79/
33 μmol/l), spont. regressive,
unclear etiology
Severe
cerebral
palsy
4 None (parents refusal) Full 4 weeks Joint Cholestasis; Giant cell hepatitis Good
5 Day 1 and 4 doses only
(week 4 dose omitted)
Full 10 weeks Skin; (after blood
sampling)
Cholestasis; α1-antitrypsin deficiency Good
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followed by weekly 1 mg oral). More aggressive (im) or
complicated (oral weekly) prophylactic regimens bear the
risk to put more parents off any prophylaxis, thus increasing
the final incidence of VKDB.
There are obvious limitations to our study. As case
detection was limited to the SPSU clinical surveillance,
underreporting of VKDB cases is possible. Dramatic
conditions such as infant (intracranial) hemorrhages are
however likely to be reported. Small umbilical or gastro-
intestinal bleeds, easily managed by general pediatricians
without coagulation studies and with additional oral VK
administrations could theoretically represent prophylactic
failure that would not be reported. Such benign conditions
would however be underreported irrespective of the VK
prophylactic regimen (oral versus im) allowing valid inter-
prophylactic regimen comparisons. Further, as the sur-
veyed units response rate of the present and 1995–2001
study were 100 %, we are fairly confident that our study
gives robust data to evaluate the efficacy of the current
Swiss VKDB prophylaxis.
In conclusions, our study supports the oral administration
of 3×2 mg mixed micellar VK (hour 4, day 4, week 4) to
prevent VKDB. Pediatricians, midwives, and parents have
to be aware of bleeding risks when any type of VK prophy-
laxis is refused. Further, pediatricians, midwives, and
parents have to be aware of early clinical signs of cholesta-
sis. To that extend, an early recognition program is being
developed in Switzerland [5]. Using van the methodology of
Hasselt et al. [12], an analysis of all biliary atresia cases that
were diagnosed in Switzerland during the present study
period is under way.
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